Neurocrine chalks up a depression drug failure [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
An experimental drug from Neurocrine Biosciences has failed a mid-stage clinical trial testing it in adults with the most common form of depression. The study enrolled 73 participants with major depressive disorder who didn't adequately respond to at least one antidepressant in their current treatment regimens. Neurocrine, without disclosing detailed data, disclosed late Monday that its drug wasn't significantly better than a placebo at curbing depression symptoms. Though the trial outcome is disappointing, there are “aspects of the data that warrant further investigation,” according to Sanjay Keswani, the company's chief medical officer. Keswani said in a statement that his team will continuing analyzing the results to “determine appropriate next steps” for the program. Neurocrine shares, which had dipped about 1.5% Monday, rebounded to be up about the same amount in after-hours trading. Neurocrine's drug, known, in short, as NBI-'770, is meant to inhibit certain brain prote
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) CapsulesPR Newswire
- Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences to Present at Upcoming Investor ConferencesPR Newswire
NBIX
Earnings
- 10/28/25 - Beat
NBIX
Sec Filings
- 12/4/25 - Form 4
- 12/3/25 - Form 144
- 12/2/25 - Form 4
- NBIX's page on the SEC website